Prelude Therapeutics Incorporated (PRLD)

NASDAQ: PRLD · USD

$4.15

+0.27 (+7.0%)· Recorded snapshot

Market cap	427.4M
Revenue (ttm)	22.4M
Net income (ttm)	-60.5M
EPS (ttm)	-$0.72
Shares out	103M
Volume	437,067
Beta	0.96

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 22.4M
Net income (ttm): -60.5M
EPS (ttm): -$0.72
Market cap: 427.4M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-57.7

P25 n/aP50 n/aP75 n/a

ROIC-33.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All PRLD indicators

Market & fundamental data

Available fields

201

Groups with data

Currency

USD

Showing 201 of 201 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001678660
Company name	Prelude Therapeutics Incorporated
Country	United States
Country code	US
CUSIP number	74065P101
Earnings date	2026-11-11
Earnings time	bmo
Employees	79
Employees change	-52
Employees growth	-39.69%
Enterprise value	$293.3M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2016
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2020-09-25
Is primary listing	Yes
Is SPAC	No
ISIN number	US74065P1012
Last 10-K release date	2026-03-10
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$427.4M
Market cap category	Small-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$4.15
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	PRLD
U.S. state	Delaware
Website	https://preludetx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-17.31%
EV/Sales	12.21x
FCF / EV yield	-12.15%
FCF yield	-8.15%
Forward EV/Sales	5.34x
Forward P/S	7.96x
P/B ratio	2.99x
P/S ratio	18.19x
Price / tangible book value	3.05x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-294.76%
EBITDA margin	-287.68%
Gross margin	100%
Operating margin	-294.76%
Pretax margin	-269.75%
Profit margin	-269.75%
Profit per employee	$-765,671
Revenue per employee	$283,848
ROA	-27.15%
ROA (5Y)	-33.75%
ROCE	-43.68%
ROE	-57.73%
ROE (5Y)	-63.52%
ROIC	-33.7%
SBC / revenue	36.99%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	5
EPS growth years	3
Gross profit growth	220.34%
Net income growth quarters	5
Net income growth years	1
Revenue growth	220.34%
Revenue growth (QoQ)	24.54%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$0
Depreciation and amortization	$1.6M
EBIT	$-66.1M
EBITDA	$-64.5M
EPS	$-0.72
FCF per share	$-0.32
Financing cash flow	$110.4M
Free cash flow	$-33.3M
Free cash flow minus SBC	$-41.5M
Gross profit	$22.4M
Investing cash flow	$-77.3M
Net cash flow	$-62,000
Net income	$-60.5M
Operating cash flow minus SBC	$-41.5M
Operating income	$-66.1M
Revenue	$22.4M
Stock-based compensation	$8.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-3.26
Book value per share	$1.30
Debt / equity	0.13
Long-term assets	$34.5M
Long-term liabilities	$17.6M
Net cash (debt)	$134.1M
Net cash / market cap	32.88%
Net cash growth	142.51%
Net debt / equity	-1
Piotroski F-Score	3
Property, plant and equipment	$30.8M
Shareholders' equity	$133.7M
Tangible book value	$133.7M
Tangible book value per share	$1.30
Total assets	$189.4M
Total cash	$151.8M
Total debt	$17.7M
Total liabilities	$55.6M
WACC	9.14%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.15
Current assets	$154.9M
Current liabilities	$38M
Current ratio	4.07
Net working capital	$-32.1M
Quick ratio	3.99
Working capital	$116.9M
Working capital turnover	0.26

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-10.91%
Dividend yield	0%
Shareholder yield	-10.91%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$4.47
1D price change	6.96%
1M price change	4.52%
1M total return	4.52%
1W price change	14.73%
1W total return	14.73%
1Y price change	136.84%
1Y return CAGR	136.98%
1Y total return	136.84%
20-day SMA	$3.66
200-day SMA	$3.99
3M price change	4.11%
3M total return	4.11%
3Y price change	123.76%
3Y return CAGR	30.79%
3Y total return	123.76%
50-day SMA	$4.54
50-day SMA vs 200-day SMA	50over200
52-week high	$6.83
52-week high date	2026-08-24
52-week low	$1.17
52-week low date	2025-11-10
5Y price change	-76.6%
5Y return CAGR	-25.22%
5Y total return	-76.6%
6M price change	-10.4%
6M total return	-10.4%
All-time high	$95.38
All-time high date	2021-02-10
All-time low	$0.61
All-time low date	2025-04-09
Average true range (ATR)	$0.30
Average volume	471.4K
Beta (1Y)	1.59
Beta (2Y)	1.3
Beta (5Y)	0.96
Change from 52-week high	-39.24%
Change from 52-week low	253.79%
Change from all-time high	-95.75%
Change from all-time low	563.83%
Change from open	4.67%
Day's gap	2.19%
Dollar volume	$1.8M
High price	$4.15
Low price	$3.95
Monthly RSI	51.63
Open price	$3.97
Position in 52-week range	100%
Premarket change	-1.8%
Premarket close	$3.88
Premarket price	$3.81
Previous close	$3.88
Price vs 150-day SMA	-9.29%
Price vs 20-day SMA	10.69%
Price vs 200-day SMA	1.4%
Price vs 50-day SMA	-10.77%
Relative volume	0.93
Return from IPO open	-84.3%
Return from IPO price	-79.16%
RSI	54.78
Sharpe ratio	1.17
Sharpe ratio (3Y)	0.74
Sharpe ratio (5Y)	0.27
Sortino ratio	2.6
Sortino ratio (3Y)	1.46
Sortino ratio (5Y)	0.54
Volume	437.1K
Weekly RSI	49.49
YTD price change	39.66%
YTD total return	39.66%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	22.1M
Float percentage	21.42%
Shares change (QoQ)	19.23%
Shares change (YoY)	10.91%
Shares held by insiders	4.38%
Shares held by institutions	20.26%
Shares outstanding	103M
Short % of float	20.74%
Short % of shares	4.44%
Short ratio	9 days

Deeper analysis on PRLD

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this PRLD report

Is a complete PRLD research report available?

No complete published report is available for Prelude Therapeutics Incorporated (PRLD) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Prelude Therapeutics Incorporated (PRLD)

Price

Financial snapshot

Fair-value bridge

Latest news · PRLD

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All PRLD indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on PRLD

Frequently asked questions